TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XDEMVY

LOTILANER
Approved 2023-07-24
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2023-07-24
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: LOTILANER

XDEMVY Approval History

Loading approval history...

What XDEMVY Treats

1 indications

XDEMVY is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Demodex Blepharitis
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XDEMVY FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis.

XDEMVY Patents & Exclusivity

Latest Patent: Dec 2038
Exclusivity: Jul 2028

Patents (9 active)

US11690827 Expires Dec 14, 2038
US11690826 Expires Dec 14, 2038
US11197847 Expires Dec 14, 2038
US10835517 Expires Dec 14, 2038
US12171750 Expires Dec 14, 2038
US11752137 Expires Dec 14, 2038
US12213964 Expires Dec 14, 2038
US12364685 Expires Dec 14, 2038
US8383659 Expires Jan 17, 2030

Exclusivity

NCE Until Jul 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.